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Abstract
Objective—Since longitudinal studies determined that anxiety is a strong risk factor for hot 
flashes, we hypothesized that an anxiogenic stimulus that signals air hunger (hypercapnic, 
normoxic gas) would trigger an exacerbated hot flash-associated increase in tail skin temperature 
(TST) in a rat ovariectomy (OVEX) model of surgical menopause and hot flashes in symptomatic 
menopausal women. We also assessed TST responses in OVEX serotonin transporter (SERT)+/− 
rats that models a common polymorphism that is associated with increased climacteric symptoms 
in menopausal women and increases in anxiety traits.
Methods—OVEX and sham-OVEX rats (initial experiment) and wildtype and SERT+/− OVEX 
rats (subsequent experiment) were exposed to a 5 min infusion of 20%CO2 normoxic gas while 
measuring TST. Menopausal women were given brief 20% and 35%CO2 challenges, and hot 
flashes were self-reported and objectively verified.
Results—Compared to controls, OVEX rats had exacerbated increases in TST, and SERT+/− 
OVEX rats had prolonged TST increases following CO2. Most women reported mild/moderate hot 
flashes after CO2 challenges, and the hot flash severity to CO2 was positively correlated with daily 
hot flash frequency.
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Conclusions—The studies demonstrate that this anxiogenic stimulus is capable of inducing 
cutaneous vasomotor responses in OVEX rats, and eliciting hot flashes in menopausal women. In 
rats, the severity of the response was mediated by loss of ovarian function and increased anxiety 
traits (SERT+/−), and, in women, by daily hot flash frequency. These findings may provide insights 
into anxiety related triggers and genetic risk factors for hot flashes in thermoneutral environments.
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Introduction
Hot flashes are intense heat sensations that occur primarily in the chest and face and affect 
the vast majority of women at midlife or following estrogen inhibition therapies or 
oophorectomy (1, 2). In the laboratory setting, the subjective hot flash sensation (as 
indicated with button press or self-report) correlates well with objectively measured, 
sympathetically-mediated increases in cutaneous vasodilation which pools 37°C blood to the 
skin. This in turn interacts with peripheral thermal sensors in skin to signal heat. Sweating 
sometimes also occurs during a hot flash, but this induces an evaporative cooling sensation. 
Under normal circumstances, both cutaneous vasodilation and sweating are effective means 
of dissipating heat to maintain core body temperature (Tc) in warmer environments. While 
environmental temperature is often thought to affect hot flash parameters (i.e., frequency, 
severity, duration), many studies have found weak or inconsequential relationships to 
ambient temperature (3-5), and in a self-reported survey of hot flash precipitants, 
temperature was identified less frequently than other stimuli (6). While exact figures are 
unavailable, these data suggest that many women may experience hot flashes in 
thermoneutral environments with no clear identifiable trigger. In these circumstances, the 
collective heat dissipation mechanisms that occur during a hot flash could lead to decreases 
in Tc which does occur and could explain chills that also occur in menopausal women [(7) 
and see review (8)].
While there are many variables that influence hot flashes, recent findings from large 
longitudinal studies have identified the presence of anxiety, early life stress, and lower 
socioeconomic status as key risk factors for more severe and problematic hot flashes (9, 10). 
Notably, anxiety has been identified as the best predictor of hot flashes, even when 
controlling for typical confounds, and women with greater anxiety levels experience more 
severe hot flashes (10, 11). Additionally, many women report that stressful stimuli in 
everyday life precipitate hot flashes (6), and stressful stimuli in a laboratory setting have 
been shown to increase objectively measured hot flashes (12). Taken together, there is 
evidence that stressful events may provoke hot flashes, and that pre-existing anxiety states or 
traits may contribute to increased symptoms. However, the mechanisms by which anxiety 
and stress-related factors contribute to hot flashes remain poorly understood.
One contributing factor to the poor understanding of the mechanisms mediating hot flashes 
is a scarcity of appropriate, validated animal modeling (13). Previous models such as the 
morphine withdrawal model (14) elicit robust cutaneous vasomotor responses in the tail, but 
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lack an obvious relevance to causes and triggers of hot flashes (15, 16). Consequently, the 
use of models for mechanistic investigation into the central and peripheral neural circuitry 
and associated pathways mediating hot flashes has suffered. Recently, we found profound 
decreases in Tc in rats following an acute 20% carbon dioxide (CO2) exposure, which 
produces anxiety-associated behavior (social and open field avoidance, fear-associated 
freezing, and avoidance of a 15-20%CO2 filled chamber in a two chamber place preference 
test) and sympathetic associated cardioexcitation (17-21). In human studies, 20%CO2 
inhalation induces anxiety symptoms (22, 23), and in another study the participants reported 
anxiety that was also associated with strong heat sensations following a single inhalation of 
35%CO2 (24). However, it was unknown if this would have relevance to menopause-
associated symptoms.
Therefore, we designed a series of studies to determine if CO2 exposure represented a novel 
method of provoking hot flashes. Thus, in a rodent model, we first hypothesized that 20% 
CO2-induced decreases in Tc were due to cutaneous vasomotor responses in the tail which 
would increase the tail skin temperature (TST) to dissipate heat in a thermoneutral 
environment. We further posited that the TST response would be exacerbated in 
ovariectomized (OVEX) rats, modeling surgical oophorectomy-induced menopause, which 
is linked to more severe hot flashes (2, 25). Second, in a small, proof of concept study, we 
hypothesized that 20% CO2 and 35% CO2 inhalation tests would elicit a subjective hot flash 
in symptomatic menopausal women. Finally, recent work has begun to elucidate some of the 
genetic contributions to increased or problematic hot flashes. The short (‘s’) version of the 
serotonin transporter (SERT) gene, whose protein product mediates the termination of 
serotonin signaling, leads to reduced transcriptional efficiency and less protein, and is linked 
to anxiety-associated traits in humans (26-29) as well as increased climacteric symptoms in 
menopausal women (30). Therefore, our last hypothesis was that OVEX rats with a 
heterozygous null mutation of the SERT gene (SERT+/−) which leads to similar reduced 
transcriptional efficiency, would have exacerbated and/or prolonged hot flashes (increased 
TST) in response to CO2 compared to wildtype (WT) OVEX controls.
Materials and Methods
Animal Experiments
Animals and Housing Conditions—Adult female (225-250 g) Sprague-Dawley rats 
were purchased from Harlan Laboratories (Indianapolis, IN USA). Rats with heterozygous 
expression of the serotonin transporter (SERT) were purchased from Charles River 
Laboratories (Wilmington, MA USA) and bred in-house on a Wistar background from 
Wistar rats purchased from Harlan Laboratories (Indianapolis, IN). These rats possess a null 
mutation of the SERT generated by N-methyl-N-nitrosurea-mutation which results in an 
approximately 50% reduction in expression of SERT mRNA within the brain as described 
previously (31). New Wistars from Harlan (Indianapolis) were bred into the colony every 
three generations to prevent genetic drift. Female Wistar rats (225-250 g) were purchased 
(Harlan, Indianapolis) as wildtype controls and were housed in the same conditions as the 
other experimental rats (maintained at 22°C on a 12:12 light/dark cycle with lights on at 
0700h) for at least 5 days prior to experimental procedures and had ad libitum access to food 
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and water. We have also confirmed that, compared to Wistar male wildtype controls, the 
male SERT−/+ rats have an approximately 50% reduction in SERT mRNA within a brain 
region densely populated with serotonergic neurons (i.e., 300uM coronal brain punches of 
dorsal and median raphe nuclei (unpublished observations). All procedures were approved 
by the Institutional Animal Care and Use Committee at Indiana University-Purdue 
University, Indianapolis, and in accordance with the NIH Guidelines for the Care and Use of 
Laboratory Animals (NIH publication no. 80-23) revised 1996.
Ovariectomy—Female rats were anesthetized under isoflurane (2-3% by volume in 
atmospheric air; MGX Research Machine, Vetamac, Rossville, IN USA; Praxair Inc., 
Indianapolis, IN USA) delivered through a nosecone. The skin was shaved and sterilized 
prior to incision; the ovaries were visualized and excised bilaterally. For sham-
ovariectomized rats, the ovaries were visualized but not excised. Rats were sutured, given 
pain medication, and allowed 12 days of recovery prior to experimental manipulations.
CO2 provocation of hot flash—Flow cages (12 in. width × 12 in. height × 24 in. length) 
were custom-built using Plexiglas®. When the lid of the cage was latched, gases could only 
enter the cage through an inlet connector (for the gas infusion) and could only exit the cage 
through an outlet connector. The gas flow into the cages was controlled using a 2-stage 
regulator (Praxair, Inc., Danbury, CT USA) at a pressure of 0.6 Bar. We previously validated 
the consistency of the rate of CO2 delivery using state-of-the-art infrared CO2 (ProCO2) and 
electrochemical O2 (ProO2) sensors (32). Specifically, concentrations of O2 remain at 21% 
throughout the gas infusion in the control and experimental cages [see (Johnson et al., 
2005)]. The CO2 concentration remains constant at < 1 % in the control cage during 
exposure of rats to atmospheric air (< 1% CO2 / 21% O2/ 79% N2). Infusion of the premixed 
normoxic, hypercapnic gas (20% CO2 / 21% O2/ 59% N2) results in a rapid increase in CO2 
concentration from < 1% CO2 up to 20% CO2 at the 5 min time point. After terminating gas 
infusion and opening the cages, the concentration of CO2 rapidly decreases from 20% CO2 
to < 2.5% CO2 during the following 5 min. Using a portable iSTAT gas analyzer (HESKA, 
Des Moines, IA USA) we have also determined that this hypercapnic, normoxic challenge 
leads to arterial pCO2/pH levels of ~ 130mmHg/7.01 during the challenge that are back to 
normal physiological range (~50mmHg/7.37) within 2 min post challenge (unpublished 
data). Prior to placement in the apparatus, a thermistor (Omega Precision Fine Wire 
Thermocouples, Part #5SRTC-TT-K-30-36; Omega Engineering, Stamford, CT USA) was 
secured to the ventral side of the tail approximately 1 cm from the base using 3M 
Durapore® tape to measure tail skin temperature. The thermistor was attached to a T-type 
pod and connected to a Powerlab system running LabChart software (ADInstruments, 
Colorado Springs, CO USA) for continuous monitoring of temperature. After obtaining a 
stable baseline temperature in atmospheric air, rats were exposed to hypercapnic gas for 5 
min, and then atmospheric air was infused again for 10 min following the challenge.
Atmospheric Air Control Experiment—To determine if the experimental environment 
alone caused a change in tail skin temperature, the above experiment was performed, but 
only atmospheric air was infused for the duration of the experiment. After obtaining a stable 
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baseline, the air was turned off and immediately turned back on to mimic the gas change 
during a CO2 infusion. Rats recovered in atmospheric air for 10 min following the challenge.
Infrared Thermography—As an additional verification of temperature change, thermal 
images were acquired following hot flash provocations using a FLIR T440 thermal imaging 
camera (FLIR Systems, Boston, MA USA) with standard settings taken at a height of 1 m. 
Analysis of images was performed using FLIR Tools to standardize scaling between thermal 
images.
Human procedures
Sample—Six peri- or post-menopausal English-speaking women with at least 4 hot flashes 
per 24 hour day were recruited. Each participant gave written informed consent after one of 
the investigators explained the nature, purpose, and risks of the study. All participants were 
screened for medical and psychiatric history. To be eligible, all participants reported daily 
hot flashes (verified on 7-day diary), were afebrile, had a resting heart rate < 110 beats per 
minute, a respiratory rate of 8-18 breaths per minute, oxygen saturation above 94%, and 
were normotensive (BP < 160/100). Women were excluded if they had respiratory or cardiac 
disease (COPD, asthma, emphysema, hyperventilation syndrome, heart disease), 
hypertension, insulin-dependent diabetes, cancer, Axis I diagnosis (depression, panic 
disorder, generalized anxiety disorder), personal/familial history of cerebral aneurysm, were 
taking any medications for hot flashes, were substance abusers (including excessive 
smoking, i.e. >10 per day), were trained athletes, or were pregnant or breastfeeding. 
Participants were compensated $50 at the end of the study.
Measures—Demographic information was elicited by the investigator using a standard 
questionnaire. Participants completed a checklist type form to provide age, race, ethnicity, 
education, menopausal status, and other information.
Hot flashes were measured as follows. Using a hot flash diary, women were asked to record 
the number and severity of their hot flashes for seven consecutive days. This information 
was used to verify eligibility. To evaluate hot flash severity during the study, participants 
completed a numeric rating scale (NRS). During the study visit, participants rated the 
severity of any reported hot flashes from 0 (not at all) to 10 (extremely) during the study 
visit, and all self-reported hot flashes were verified with objective sternal skin conductance 
monitoring (Biolog, UFI Serving Science, Morro Bay, CA USA).
Anxiety was rated using two self-report scales. Using a numeric rating scale (NRS) of 0 (not 
at all) to 10 (extremely), participants rated how anxious they felt at baseline, after the control 
room air inhalation, after the CO2 challenge conditions, and at discharge. Higher scores on 
the NRS indicated greater anxiety. In addition, participants also completed the State version 
of the short form of the State-Trait Anxiety Inventory, a 10-item inventory, to assess anxiety 
“in the moment”. All items on the scale are positively worded (e.g., I feel calm) and each 
item is rated from 1 (not at all) to 4 (very much so) so that higher total scores indicate less 
state anxiety. The STAI was completed at baseline and immediately prior to discharge.
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Procedures—Procedures were HIPAA compliant and approved by the Indiana University-
Purdue University, Indianapolis Institutional Review Board prior to study implementation. 
Women were recruited through self-referral and emails to potentially eligible research 
registry members. For registry participants, once emails had been sent by the registry, the 
research team attempted to contact each woman by telephone. Self-referrals phoned or 
emailed the research team on their own. Once contact was made with a potential participant, 
trained personnel used a script to screen them for eligibility. If eligible, women were emailed 
the hot flash diary and instructed on how to complete it. Once diary responses were sent via 
phone, email, mail or secure fax, eligibility was confirmed (i.e., daily hot flashes met 
threshold) and study visits were scheduled at a mutually convenient time. Email or phone 
call reminders were done prior to study visits.
Each participant arrived at the university Clinical Research Center at a pre-determined time. 
Written informed consent and authorization to use health information was obtained. Trained 
research staff assessed baseline vital signs (heart rate, respiratory rate, blood pressure, and 
temperature), peripheral oxygen saturation levels, and height and weight, and women were 
connected to the hot flash monitor. Next, demographic information and anxiety scales 
(STAI, NRS) were completed. A non-rebreather mask was fitted for each participant. 
Through this mask, the participant inhaled normal room air for 10 minutes to become 
acclimated to the mask. The anxiety NRS was completed by the participant, followed by a 3-
minute rest period. Next, the participant inhaled 20% CO2 for 40 seconds via the mask. The 
hot flash NRS and the anxiety NRS were completed, followed by a 15-minute rest (the rest 
period was extended by 5 minutes if the participant had a hot flash), and then a vital-
capacity, double-breath inhalation of 35% CO2. A final anxiety NRS and STAI anxiety were 
completed by the participant; see Fig. 2a for a schematic of study procedures. As mentioned 
in the introduction, 20% and 35% CO2 inhalation procedures have been utilized previously 
with healthy humans to induce and study anxiety symptoms (23) and reliably produce stable 
autonomic responses, including increases in skin conductance and heart rate, across multiple 
sessions (33). Here we utilized the NRS to measure anxiety symptoms at baseline, following 
mask and control air and immediately post CO2 inhalation, but the NRS and STAI were also 
utilized to verify that there were no lingering anxiety effects 15-20 min post CO2 inhalation. 
Previous work has demonstrated that there are no increases in severe anxiety at 6 and 12 
months following 20% CO2 challenges [compared to participants exposed to control 
conditions; (34)]. Vital signs were taken and the participant was discharged to home.
Statistical Analyses—For animal experiments, dependent variables for analyses of tail 
skin temperature (TST) were analyzed using a one-way ANOVA with repeated measures, 
using gas infusion as the between-subjects factor and time as a within-subjects factor. In the 
presence of significant main effects or main effect × time interactions, Fisher’s Least 
Significant Difference (LSD) test was used for post hoc testing between-subjects 
comparisons. For the clinical component, an ANOVA over time was used to determine the 
effect of 20% CO2 on NRS anxiety scores; Dunnett’s post hoc test was used to determine 
specific time point differences. Pearson’s correlation was used to determine relationships 
between hot flash frequency (daytime, nighttime, and average daily) and NRS anxiety scores 
or hot flash intensity following 20% CO2 or 35%CO2 challenges. The alpha level was set at 
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0.05 in all cases. All statistical analyses were carried out using SPSS 21.0 (SPSS Inc., 
Chicago, IL, USA), and all graphs were generated using SigmaPlot 12.0 (SPSS Inc.) and an 
illustration program (CorelDraw X5 for Windows, Viglen Ltd., Alperton, UK).
Results
Experiments 1-2: Ovariectomized rats exhibit exacerbated hot flash-associated increases 
in tail skin temperature in response to hypercapnic gas infusion while atmospheric air 
infusion does not change tail skin temperature
An ANOVA with ovex surgery and hypercapnic gas/CO2 as main factors and time as a 
repeated measure revealed that hypercapnic gas infusion produced an exacerbated increase 
in tail skin temperature in ovex rats while atmospheric air caused no changes in temperature 
[Fig 1a-Representative thermal image; Fig. 1b- CO2 tail skin temperature (n=15/group) 
overall CO2 effect F(1,38)=45.9, p<0.0001, overall ovex effect F(1,38)=5.3, p=0.027, and 
overall CO2 by time interaction F(114,532)=20.1, p<0.0001 but no ovex by time interaction 
F(14,532)=0.23, p=0.999 or ovex by CO2 by time interaction F(14,532)=0.34, p=0.989]. 
Fisher’s Least Significant Difference Test was used for post hoc testing to determine specific 
time point differences between groups, and Dunnett’s test was used to determine 
significance of specific time points against t-1.
Experiment 3: CO2 challenges elicit hot flashes in symptomatic women
A total of 113 women were contacted (109 research registry and 4 self-referrals). Of these 
113, 56 were successfully reached and completely screened for eligibility. Of the 56, 37 
were not eligible and 7 were not interested, leaving 12 eligible and interested women. These 
12 women were sent diaries but 5 were not eligible on diary return and 1 did not return her 
diary. Of the remaining 6 women, all completed the study visit.
Sample demographics were as follows for the five participants that successfully completed at 
least one CO2 inhalation. The participants had a mean age of 49.8 (SD=2.77) and 17.00 
years of education (SD=3.32). Four of five participants were were non-Hispanic White and 
one was non-Hispanic Black, 4/5 were married (1 was other), 4/5 reported no difficulty 
paying for basics (1 reported some difficulty), and all worked full-time outside the home. 
Comorbidities included hypothyroidism (n=1), chronic interstitial cystitis (n=1), and non-
insulin dependent diabetes (n=1). Total number of prescription medications taken per 
participant was 1.00 (SD=1.0, range 0 to 3).
The screening week hot flash diaries showed an average of 7.00 hot flashes during the 
daytime (SD=4.15, range 3.42 to 13.57), and 3.29 hot flashes during the nighttime 
(SD=0.96, range 2.29 to 4.86), for an average of 10.29 total hot flashes per 24-hours per 
participant (SD=4.24, range 5.86 to 16.43).
Five of six participants reported hot flashes after CO2 challenge (see Fig. 2b). One 
participant had no confirmed inhalations during either CO2 challenge and was removed from 
all analyses. Three of the four participants with confirmed inhalations of 20% CO2 reported 
hot flashes within 5 min of the challenge that ranged from mild to moderate, and two of the 
three participants with confirmed inhalations of 35% CO2 reported a hot flash within 5 min 
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of the challenge. Numbers below “NRS hot flashes post CO2” respectively represent hot 
flash severity rating following 20%CO2 (Fig. 2b column 9), and 35%CO2 with the 
parenthetical number representing the mean NRS of confirmed inhalations; a “-” indicates 
no confirmed inhalation which was evidenced by removal of the mask and coughing, or 
confirmation that inhalations were not completed. Numbers below “NRS anxiety post CO2” 
respectively represent 20%CO2 and 35%CO2 (Fig. 2b, column 10, a “-” indicates no 
confirmed inhalation). Average severity of CO2-induced hot flashes was a 4 (range 3-5) after 
20% CO2, and 2.5 (range 1-4) after 35% CO2. NRS ratings of anxiety approached 
significance following inhalation of 20%CO2, when compared to NRS anxiety ratings post 
inhalation of air (p=0.062 with paired Wilcoxon post hoc test). However, there was a 
positive correlation between average total number of hot flashes per day and the mean hot 
flash severity following confirmed CO2 inhalations, r=0.921, p=0.026, n=5 (Fig. 2c). There 
was a positive correlation between average total number of hot flashes per day and NRS 
scores for anxiety following verified CO2 inhalation, r=0.942, p=0.016, n=5. (Fig. 2d). There 
was a positive correlation between NRS hot flash severity following confirmed CO2 
inhalation and NRS anxiety following confirmed inhalation, r=0.877, p=0.049, n=5 (Fig. 
2e). Vital signs were in the normal range at the end of the study visit for all participants, and 
there were no lingering effects on anxiety or vital signs. STAI scores of 39 to 40 out of 40 
possible (no anxiety) were measured in all participants at both baseline and end of the study 
visit.
Experiment 4: Ovariectomized SERT+/− rats exhibit prolonged hot flash-associated 
increases in tail skin temperature in response to hypercapnic gas infusion
An ANOVA with genotype as the main factor and time as a repeated measure revealed that 
hypercapnic gas infusion produced a prolonged increase in tail skin temperature in ovex rats 
[Fig 3a- Representative thermal image; Fig. 3b- CO2 tail skin temperature (n=7,8) overall 
time effect F(13,392)=47.8, p<0.0001 and overall genotype × time interaction F(15,180)=2.1, 
p=0.013]. Fisher’s Least Significant Difference Test was used for post hoc testing to 
determine specific time point differences, and Dunnett’s test was used to determine 
significance of specific time points against t-1.
Discussion
These studies have demonstrated that an anxiogenic stimulus can precipitate an exacerbated 
hot flash-associated increase in TST responses in OVEX rats compared to sham-OVEX 
controls, which, to the best of our knowledge, is the first demonstration of threshold 
differences between OVEX and intact rats in response to CO2. Following similar CO2 
inhalations, symptomatic menopausal women reported mild to moderate objectively verified 
hot flashes which approached significance for an increase in anxiety ratings following 20% 
CO2 inhalation. The mean number of daily hot flashes was positively correlated with the 
severity of hot flashes and anxiety ratings post confirmed inhalations of CO2. Our studies 
provide potential insights into triggers of hot flashes in thermoneutral environments and 
evidence that anxiety or anxiety-generating stimuli may have a causal relationship to hot 
flashes, not merely an associative one. Earlier clinical provocations used the drug yohimbine 
to facilitate hot flashes (35), which, at high doses, elicits strong anxiety (36, 37), and also 
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produces robust TST responses in OVEX rats (38), and thus yohimbine may represent a 
pharmacological model preclinically and clinically. A weakness of the present rodent studies 
was that only CO2 was used as a stressor. However, we recently demonstrated that the 
GABAergic compound FG-7142 (a partial inverse benzodiazepine receptor agonist) which 
causes anxiety and flushing clinically (39) elicited rapid hot flash-associated increases in 
TST in OVEX rats but not sham control rats (40). Other studies have previously documented 
that stress-related stimuli, including mental arithmetic or emotionally salient films, can 
increase the rate of objective and subjective hot flashes (12) and self-reports implicate 
stressful stimuli (e.g. interpersonal family conflict or social stress) precipitate hot flashes in 
breast cancer patients (6). These data complement the emerging literature relating to the role 
of anxiety and stress-related factors in hot flashes and may help to start addressing a critical 
gap in knowledge of hot flash triggers.
In our preclinical rodent experiments, the results exhibit validity in three domains: 1) face 
validity, as the increase in TST is a rapid heat loss mechanism (cutaneous vasodilation) 
analogous to and what would be expected during a hot flash; 2) construct validity, as the 
TST change is exaggerated in ovariectomized rats, which is a model of surgical/
oophorectomy-induced menopause in women (a condition with more severe hot flashes (2, 
25)); and 3) predictive validity, as the same stimulus causes subjective hot flashes in 
menopausal women, and is exacerbated in ovariectomized SERT+/− rats, which mimic a 
common human polymorphism that was recently linked to increased hot flash pathology 
(30).
This modeling approach is unique in that the provocation does not use pharmacological 
manipulations; rather, it triggers an endogenous challenge to homeostasis by provoking air 
hunger through CO2 exposure. It is important to note that increasing concentrations of CO2 
in the blood combine with water to form carbonic acid to induce acidosis, and CO2 also 
easily crosses the blood-brain barrier to interact with central chemoreceptive systems (41, 
42). The 20%CO2 exposure used here produces a brief drop in blood pH to ~7.1-7.2 (19), 
and also alters pH within anxiety brain circuits (21). Importantly, these studies suggest that 
disease states or conditions associated with respiratory or metabolic acidosis may be risk 
factors for hot flashes and may reduce the threshold for a hot flash to occur. Such conditions 
include chronic obstructive pulmonary disease [COPD; pH has been reported to be 
decreased to 7.35 during sleep (43), diabetic ketoacidosis [pH 7.2 with a range of 6.78-7.39 
(44), and other factors that make breathing (and expiring adequate CO2) difficult, such as in 
smokers, asthmatic persons, or obese persons. Indeed, obesity and smoking are well-
established risk factors for hot flashes (45, 46). Additionally, stress induced hypoventilation 
or environments with poor ventilation and higher than normal levels of CO2 could contribute 
to lowering the hot flash threshold by inducing dyspnea. Finally, the anxiety response to 
acidosis or other stressors may also be relevant triggers and not just a response to the hot 
flash. Changes in pH are revealing in light of other work that has demonstrated a key role for 
pH in regard to thermoregulation and anxiety. The amygdala, a key brain structure for fear 
processing and anxiety, and 20%CO2 exposure used here produces acidosis in the amygdala, 
and local induction of acidosis induces robust fear associated freezing in mice (21). In 
persons with limbic encephalitis, which reversibly lesions the amygdala, emotional sweating 
is absent, yet thermoregulatory sweating was intact (47). Thus, emotional stimuli and 
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emotional circuits also appear to be relevant to hot flashes, and it is possible that under 
conditions of reduced pH or elevated CO2 (which causes some peripheral vasodilation), 
anxiety is elicited and emotional sweating occurs. This anxiety, in combination with 
environmental conditions (i.e., slightly increased ambient temperature) may further 
exacerbate the heat dissipation response and trigger a hot flash.
Currently, the role of blood pH in hot flashes is largely unknown. Paced respiration (which 
could moderate blood pH) such as controlled breathing of 6-10 breaths per minute, is often 
recommended as a non-pharmacological treatment for reducing hot flashes, yet clinical trials 
have not demonstrated significantly greater efficacy than usual treatment or active 
comparators (48-50).
Here our challenges utilized systemic administration through either a mask or environmental 
exposure (the latter necessitating inhalation leading to systemic exposure). Dissection of the 
central and peripheral components of the CO2-induced hot flashes and TST responses in rats 
is beyond the scope of this investigation, but the paradigms we used most likely triggered 
central mechanisms, as previous applications were used to elicit and study anxiety in 
humans and in rodents that are accompanied by sympathetic associated cardiovascular 
responses. However, CO2 has also been shown to have local cutaneous vasodilatory action in 
both humans and rodents (51, 52). Thus, there are likely central and peripheral contributions 
to hot flashes (53).
In this case, evidence for central mechanisms comes from ex vivo assessments of cellular 
responses in rodents where 20%CO2 exposure increases activity in anxiety and 
thermoregulatory associated brain circuitry such as the hypothalamus and brainstem (18, 
32). Within the hypothalamus, there is substantial overlap between nuclei that respond to 
20% CO2 and expression patterns of estrogen receptors α and β (ERα, ERβ). Specifically, 
the paraventricular nucleus responds strongly to hypercapnic gas, and also has very dense 
expression of both ERβ (54) and an excitatory transmembrane estrogen receptor (e.g., 
GRP30) (55), whereas the more posterior hypothalamic regions are similarly responsive to 
CO2 yet expresses ERα (54) and GRP30 (55). Noradrenergic and serotonergic neurons in 
the midbrain pons and medulla also exhibit hypercapnic responsivity (28). Hypothalamic 
and brainstem sites including serotonergic nuclei (dorsal raphe and raphe pallidus) and 
noradrenergic nuclei (locus ceruleus) were found to significantly increase in response to 
FG-7142 hot flash provocation as well (40). These latter sites may be especially relevant to 
hot flashes in women because both the noradrenergic and serotonergic systems are 
treatments for hot flashes with selective serotonin and/or norepinephrine reuptake inhibitors 
(56, 57). Taken together, these results provide additional validity that the neural mechanisms 
mediating cutaneous vasomotor responses induced by CO2 may be relevant to spontaneous 
hot flashes.
Our rodent studies also contribute to an emerging literature concerning the 5-HTTLPR on 
climacteric symptoms and anxiety trait vulnerability. Short form ‘s’ carriers (s/s or s/l 
genotype) of the 5-HTTLPR experience higher rates of psychiatric disorders later in life, 
including anxiety and depression (27-29, 58), which are two conditions that have been 
linked to increased hot flashes (10, 59). Analyses from the multiethnic Study of Women’s 
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Heath Across the Nation Mental Health Study found that early life stress (childhood abuse 
or neglect) also predicted later vasomotor symptoms (9). Menopausal women with the short 
form (‘s’ carrier) of the 5-HTTLPR also experience increased climacteric symptoms (30), 
which could be related to increased anxiety traits associated with this polymorphism. This 
animal model could contribute mechanistic insight into the interactions between early life 
events, genetic contributions, and later anxiety and physiological phenotypes, including hot 
flash-associated responses, which may ultimately lead to a better understanding of the role 
of serotonin and its complement of proteins to menopausal symptoms.
Indeed, this is an important research area in women’s health at midlife, as drugs that target 
the serotonin transporter are among the most frequently used pharmacotherapies for 
vasomotor symptom relief and currently represent the only FDA-approved non-hormonal 
treatment for hot flashes (60, 61). Despite this indication, SSRIs do not fully alleviate hot 
flashes and treatment switching is common due to tolerability issues (62). Some of this 
variability in response and side effects may be due to differences in SERT genotype, as 
persons with the s/s genotype have been shown to have a poor response to SSRIs (for 
treating anxiety disorders) (63). Specifically, s/s carriers are at greater risk for treatment-
emergent side effects from these medications (64). Investigations into 5-HTTLPR genotype 
by hot flash treatment efficacy could prove useful in advancing personalized medicine by 
informing treatment strategies, though to our knowledge, no such studies have been 
performed. This is likely to be a substantial challenge, as there is evidence that the effect of 
the polymorphism can be complex and modulated by ethnic background; for example the ‘l’ 
allele, as opposed to the ‘s’ allele, confers increased risk for anxiety in a Chinese population 
(65).
Limitations and Future Directions
The sample size for our clinical component was small, but reflects a pilot investigation 
design. A follow-up study with a larger and more clinically diverse sample, including s/s or 
s/l carriers, women taking estrogen or other medications for hot flashes and those with 
additional risk factors such as asthma, is warranted to further validate this method and 
preclinical results. We would like to further delineate the prevalence and intensity of hot 
flashes following CO2 inhalation at different concentrations and accompanying 
physiological events (i.e. skin conductance and temperature, core body temperature, 
cardiovascular profile, and blood chemistry, including pH throughout the laboratory session) 
and time course of evoked hot flashes. These are important considerations, because current 
procedures to elicit hot flashes in a clinical study typically use warming methods, such as 
water-perfused suits and/or heating pads(66) which are relevant to hot flashes occurring in 
warm environments but have questionable validity for hot flashes occurring in thermoneutral 
environments. In addition, these methods can require up to 20 minutes for a hot flash to 
occur. Importantly, while the ratings of severity of the hot flashes in this preliminary 
investigation were mild to moderate, we did note that the subjective hot flash intensity 
appeared to be worse in menopausal women with more frequent hot flashes, though with the 
small sample size, these correlations should be considered cautiously. Future studies will 
also need to determine how pre-existing anxiety or stress contributes to the presentation of 
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objective and subjective hot flashes post stress-induced hot flashes (e.g., mental arithmetic, 
emotionally salient films, or hypercapnic gas inhalation).
Potential Clinical Value
These studies demonstrated a novel method of provoking a hot flash using CO2 inhalation 
and suggests that decreased breathing during stress, or conditions associated with acidosis 
[e.g. respiratory (e.g., COPD, bronchitis, or asthma) or metabolic (e.g., diabetes or lactic 
acidosis)] may increase the risk for hot flashes by reducing the threshold for hot flashes to 
occur, especially in combination with anxiety or thermal associated stimuli. Further study is 
warranted to fully validate this method, as our sample size was small and limited to 
otherwise healthy symptomatic women. A fine-grained delineation of the response to CO2 
will allow reverse translational studies (in highly controlled environments) that have the 
potential to help elucidate mechanisms underlying hot flashes.
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Figure 1. Rats modeling surgical menopause exhibit exacerbated hot flash-associated tail skin 
temperature responses
Effects of ovariectomy or sham surgery on baseline tail skin temperature in response to 
hypercapnic or atmospheric air infusion. a) Representative thermal images with scale (to the 
right) of a sham-OVEX (top) or OVEX rat (bottom) after 5 min exposure to atmospheric air 
(left) or 20% CO2 (right). b) Line graph with error bars (SEM) represents mean tail skin 
temperature prior to and following atmospheric air or hypercapnic gas challenge in OVEX 
or sham-OVEX groups assessed with a tail thermistor at the base of the tail (n=15/group for 
CO2 challenge and n=6/group for atmospheric air challenge). *denotes significance of 
surgical treatment at specific time points in (b) with Fisher’s Least Significant Difference 
test protected by an ANOVA, and + denotes significant differences over time from t-1 as 
measured by Dunnett’s test.
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Figure 2. Small clinical study of hot flash provocation with CO2 challenges in highly 
symptomatic women
a) Timeline for the study procedures; a room air acclimation (through a mask) was given for 
10 min prior to a rest period before a 40s, 20% CO2 (normoxic) challenge. Participants 
rested for 15-20 min prior to the 35% CO2 administration. b) Table illustrates participants 
assigned number, age, total hot flashes during the day and night for a 7 day period prior to 
the study, average hot flashes per day, baseline STAI and NRS anxiety, NRS anxiety post 
control air, NRS hot flash and anxiety (respectively) severity post 20% and 35% CO2 
inhalation, followed by the NRS Anxiety and STAI anxiety at rest. Participants are ranked in 
order of increasing daily hot flashes. 3 of the 4 participants, and 2 of the 3 participants with 
confirmed inhalations of 20% CO2 and 35%CO2 reported hot flashes within 5 min, 
respectively; hot flashes were rated from mild to moderate. Numbers below NRS hot flashes 
or anxiety (columns 9 and 10, respectively) post CO2 respectively represent 20% CO2 and 
35% CO2 with the parenthetical number representing the mean of the confirmed inhalations 
(“-” indicates no confirmed inhalation for respective challenge). Correlation analyses 
revealed that the frequency of daily hot flashes (total per 24h day) was positively correlated 
with the c) mean severity of the hot flash post confirmed CO2 inhalations and d) mean 
severity of the anxiety response post confirmed CO2 inhalations. Correlation analysis also 
demonstrated that the e) mean hot flash severity following verified CO2 inhalation was 
positively correlated with the mean anxiety rating following verified CO2 inhalation.
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Figure 3. Rats with a heterozygous null mutation of the serotonin transporter (SERT+/−) have 
prolonged hot flash-associated tail responses to hypercapnic gas infusion
Effects of ovariectomy in SERT+/− and WT rats tail skin temperature in response to 
hypercapnic gas infusion. a) Representative thermal image with scale (to the right) of a WT-
ovex (top) or SERT+/− rat (bottom) after 5 min exposure to 20% CO2. b) Line graph with 
error bars (SEM) represents mean tail skin temperature prior to and following hypercapnic 
gas challenge in ovex SERT+/− or WT rats assessed with a tail thermistor at the base of the 
tail (n=8,7). *denotes significant effect of estrogen treatment with a two-way ANOVA 
p=0.001 in (a). *denotes significance of genotype at specific time points in (c) with Fisher’s 
Least Significant Difference test protected by an ANOVA, and + denotes significant 
differences over time from t-1 as measured by Dunnett’s test.
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